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Benefit sharing: combining intellectual property, trade secrets, science and an ecosystem-
focussed approach  
Marcel Jaspars and Abbe E. L Brown  
Abstract 
This contribution develops a new approach to benefit sharing in areas beyond national 
jurisdiction. It has regard to a breadth of relevant legal regimes, sustainability, the needs of 
science, analogies with Farmers Rights and the prospect of increased involvement of the 
commercial sector. Proposals are made for the benefit sharing regime to cover digital 
sequences of marine genetic resources; for restrictions to be imposed on the rights of IP 
owners and controllers of trade secrets to enable delivery of a balanced approach to benefit 
sharing; for an open sharing of the results of research cruises; for a pragmatic and deliverable 
approach to tracing use of marine genetic resources across present and future development 
pipelines; and for different approaches to be taken to benefit sharing in respect of 
ecologically sustainable technologies, to encourage their pursuit.  The proposals are marked 
in italics.        
 
1. Introduction  
 
This interdisciplinary contribution made from law and science develops proposals to deliver a 
pragmatic means of the sharing of the benefit arising from use of marine genetic resources 
(MGR). Benefit sharing of MGR is one of the issues covered by a commitment under the 
United Nations Convention on the Law of the Sea (UNCLOS)1 to create an internationally 
binding legal instrument (ILBI) on the conservation and sustainable use of marine biological 
diversity of areas beyond national jurisdiction (ABNJ).2  This proceeds in the context of 
MGR’s importance being highlighted at the Intergovernmental Panel on Climate Change 
meeting in Monaco in 2019, given its potential contribution to industry transition and nature-
based solutions.3  This and other uses of MGR require work with unexplored and extreme 
 
1 United Nations Convention on the Law of the Sea 1833 UNTS p 3. For general discussion of marine 
environmental protection under UNCLOS see J Harrison, Saving the Oceans through Law. The International 
Legal Framework for the Protection of the Marine Environment, (Oxford, Oxford Univeristy Press, 2017) 17-
63. 
2 Ibid 296-9; R Warner, ‘Oceans of Opportunity and Challenge: Towards a Stronger Governance Framework for 
Conservation and Sustainable Use of Biodiversity in Marine Areas Beyond National Jurisdiction’ 3 Asia-Pacific 
Journal of Ocean Law and Policy (2018) 157 (Warner). See also United Nations webpage Intergovernmental 
Conference on Marine Biodiversity of Areas Beyond National Jurisdiction https://www.un.org/bbnj/ accessed 2 
November 2019 (UN site). Reference is made below (see n24-7) to specific resolutions made in this process.   
3  IPCC, ‘Special Report on the Ocean and Cyrosphere in a Changing Climate’ (2019) 
https://www.ipcc.ch/srocc/home/ accessed 2 November 2019.   
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environments such as the cryosphere, deep oceans and thermal vents4 - and all of these can be 
found within ANBJ.5   
Benefit sharing will be developed here by taking an ecological and ecosystem approach, 
reflecting the climate change intersection just noted; by including genetic sequence 
information about MGR, as well as physical MGR samples, which reflects evolving scientific 
realities; by engaging with intellectual property (IP) rights and trade secrets reflecting the 
contribution these rights can make to delivery (and non delivery) of benefit sharing; by 
engaging more deeply with tracing and digital identifers; and by evaluating how widely 
benefit sharing could and should extend along the research and commercialisation pipeline, 
which reflects the need to reward, incentivise and increase knowledge development, 
information sharing and coordination as well as investment.  A new means of benefit sharing 
will be put forward which combines respect for sustainability, different relevant laws and 
scientific reality and workability.   
2 The journey to the sharing of benefits from MGR in the ABNJ 
 
2.1 The scientific pathway 
UNCLOS, adopted in 1992, did not address MGR, even though deep sea biodiversity has 
been known since the Challenger expeditions explored the north and south Atlantic and the 
Pacific in 1872-6. 6   It has been suggested that UNCLOS’s position arose from the fact that 
the value of deep-sea marine biodiversity was not generally appreciated until the 1990s, with 
technology not being available to exploit the resources;7 and conversely that MGR was 
deliberately not addressed because of uncertainty as to how to balance the interests of the 
commercial sector with enabling all (in particular scientists) to benefit in different ways from 
the use of these resources.8   
 
4 See eg Industrial Biotechnology Innovation and Growth Team, ‘Maximising UK Opportunities from Industrial 
Biotechnology in a Low Carbon Economy. A report to the government by the Industrial Biotechnology 
Innovation and Growth Team’ (IB 2025, May 2009) 
http://beaconwales.org/uploads/resources/Maximising_UK_Opportunities_from_Industrial_Biotechnology_in_a
_Low_Carbon_Economy.pdf accessed 2 November 2019 
5 J Cone, Fire under the Sea. The Discovery of the Most Extraordinary Environment on Earth – volcanic hot 
springs on the ocean floor (New York, William Morrow and Co, 1991); Royal Society, ‘Future ocean resources: 
metal-rich minerals and genetics – evidence back’ (2017)  
https://royalsociety.org/~/media/policy/projects/future-oceans-resources/future-of-oceans-evidence-pack.pdf 
accessed 2 November 2019 (Royal Society) 39-41. 
6  The Challenger Society for Marine Science, ‘The History of the Challenger Expedition’ 
https://www.challenger-society.org.uk/History_of_the_Challenger_Expedition accessed 2 November 2019  
7 D.Freestone, ‘The UN Process to Develop an International Legally Binding Instrument under the 1982 Law of 
the Sea Convention: Issues and Challenges’ 3-5 in D. Freestone (ed) Conserving Biodiversity in Areas Beyond 
National Jurisdiction (Leidon, Brill Nijhoff, 2019) (Freestone). 
8A landmark piece is L. Glowka, ‘The Deepest of Ironies: Genetic Resouces, Marine Scientific Research, and 
the Area’ 12(1) Ocean Yearbook Online (1996) 154. See also R. Tiller et al, ‘The once and future treaty: 
Towards a new regime for biodiversity in areas beyond national jurisdiction’ 99 Marine Policy (2019) 239-242, 
1.4; C. Correa, ‘Access to and Benefit Sharing of Marine Genetic Resources Beyond National Jurisdiction: 
Developing a new Legally Binding Instrument’ South Centre Research Paper 79 Sept 2017 (Correa).    
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Access to deep sea biodiversity is indeed challenging because of the level of engineering and 
financial input (including research vessels, deep sea sampling systems and remotely operated 
vehicles) which is needed to collect MGRs.9 Yet awareness of the commercial and societal 
gain which could arise as a result grew over time.10  From 1969 onwards, there was work on 
reef organisms such as sponges, seasquirts and soft corals and from the early 1990s scientists 
investigated marine bacteria from marine sediments (which are easier and less expensive to 
collect) for microbially-derived compounds to provide novel bioactive molecules. 11  In the 
early 21st century, there were some successes in use of MGR derived clinical application of 
anti-cancer medicines, but industrial natural product drug discovery was then de-emphasised 
as industry pursued, fairly unsuccessfully, more technological paths such as combinatorial 
chemistry and high-throughput screening methods.12  This, and growing understanding of the 
molecular mechanisms by which bioactive natural products are made, means that natural 
product drug discovery is experiencing a resurgence at the time of writing in 2019.13 It has 
been said that “sustainable use of these novel resources could have significant benefits…… 
The high biodiversity in the ocean, including species adapted to a range of extreme 
environments provides a substantial resource for development of new chemicals, including 
antibiotics and cancer treatments”.14 Opportunities also lie in delivering bioenergy and 
ecological solutions, cosmetics, household products and nutraceuticals.15   
2.2 Legal pathways 
Uncertainty continues about the extent to which these opportunities will come about - 
consider that in 2017, 30,000 relevant molecules had been identified and 9 related products 
had been brought to market -  however, the pipeline appears to be becoming more 
productive.16  Given this prospect of greater commercial interest in MGR, it is timely that the 
United Nations is addressing conservation and sustainable use of MGR, including the sharing 
 
9A Jamieson, The Hadal Zone: Life in the Deepest Oceans (Cambridge, Cambridge University Press, 2015), Part 
I.   
10 K. ten Kate and S. A Laird, The Commercial use of biodiversity: access to genetic resources and benefit-
sharing (London, Earthscan, 1999) (Kate/Laird) 3.3.3, 9.  
11 See Midwestern University, ‘Clinical Pipeline: Marine Pharmacology.  Approved Marine Drugs’  
https://www.midwestern.edu/departments/marinepharmacology/clinical-pipeline.xml accessed 2 November 
2019. 
12See T Kodadek, ‘The rise, fall and reinvention of combinatorial chemistry’ 55 Chemical Communications 
(2011) 47, 9757-9763  
13S. Pearce, ‘A Resurgence in Natural Product-Based Drug Discovery: Advances in analytical technology are 
making the screening of natural products and their substructures more viable’ 13(2) PharmTech (2018) 
http://www.pharmtech.com/resurgence-natural-product-based-drug-discovery accessed 2 November 2019. 
14 Royal Society n5 5, and more detailed analysis of MGR 32-6, with discussions of uses from 43 
15 R Blasiak et al, ‘The Ocean Genome: Conservation and the Fair, Equitable and Sustainable Use of Marine 
Genetic Resources’ (High Level Panel for a Sustainable Ocean Economy)  https://oceanpanel.org/ocean-
genome-conservation-and-fair-equitable-and-sustainable-use-marine-genetic-resources accessed 2 November 
2019 (Blasiak). 
16 Royal Society, 42-3; see also Correa n8, 4, 6 referring to Pharmasea project on which Jaspars was involved, 
see http://www.pharma-sea.eu/ accessed 2 November 2019; D. Skropeta, ‘Deep-sea natural products’ 25 
Natural Products Reports (2008) 1131-1166 reviewing 390 marine natural products from deep water to 2007;   
E Heafey ‘Access and Benefit Sharing of Marine Genetic Resources from Areas beyond National Jurisdiction: 
Intellectual Property--Friend, Not Foe’ 14(2) Chicago Journal of International Law 2014, Article 5 (Heafey), 
495-6; Correa, 15-6 referring to 2015 report of National Institute of Genetics 
https://www.nig.ac.jp/nig/pdf/about_nig/youran2014.pdf accessed 2 November 2019.  
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of benefit derived from these. Industry has met nature before - on land and in ocean areas 
which are within national jurisdiction, leading to the Convention on Biological Diversity 
199217 and then the Nagoya Protocol on fair and equitable sharing of benefits. 18   Nagoya 
does not address the needs of MGR in ABNJ as it takes in the main a bilateral approach and 
under UNCLOS no one can own or transfer resources from the ABNJ.19  Yet a common 
theme in these UNCLOS discussions is the risk of taking an approach to benefit sharing in 
ABNJ which is too radically different to Nagoya; this is because it could create extra burdens 
on capacity, given that some forms of MGR (say the larvae from sponges) may be found 
within and outside national jurdsiction or move from one to the other.20 
For MGR in ABNJ, the international policy start came in 2004 when the UN General 
Assembly21  established an Ad Hoc Open Ended informal working group (Working Group) to 
study issues relating to the conservation and sustainable use of marine biological diversity 
beyond areas of national jurisdiction.22 The Rio plus 20 meeting in 2012 of the United 
Nations Conference on Sustainable Development referred to the Working Group and called 
for the ABNJ to be addressed at UNCLOS.23 In 2015 a United Nations General Assembly 
resolution24 established a Preparatory Committee to make recommendations on elements of a 
text, taking into account reports of the Working Group.25 In 2018, the UN General 
Assembly26 convened an Intergovernmental Conference (IGC) to consider the 
recommendations of the Preparatory Committee and to develop the text of an IBLI to address 
conserving ensuring sustainable use of biodiversity in particular “together and as a whole”, 27 
MGR and access and benefit sharing (the focus here), area based management tools including 
marine protected areas,  environmental impact assessments, technology transfer and capacity 
 
17 Convention on Biological Diversity 1992 1760 UNTS p39, arts 1, 15 (in particular (3) and (7)), 16, 19, 20, 21. 
18 See text https://www.cbd.int/abs/text/  accessed 2 November 2019. See in particular art 10 and analysis in E. 
Morgera, E Tsiomani and M. Buck eds) Unraveling the Nagoya Protocol – A Commentary on the Nagoya 
Protocol on Access and Benefit-sharing to the Convention on Biological Diversity (Leiden, Brill, 2014) 
(Morgera et al). 
19 Nagoya Protocol, art 6(1) prior informed consent although note art 10 regardoing discussion about global 
syste, 6(3), 7, 8 regarding mutually agreed terms; UNCLOS art 137(2) - there are possibilities in respect of 
minerals.  
20M. R. Muller, Genetic Resources as Natural Information: Implications for the Convention on Biological 
Diversity and Nagoya Protocol (Abingon, Earthscan/Routledge, 2015) (Muller), 39-41, 67.  
21 GA59/24 para 73  
22See webpages https://www.un.org/Depts/los/biodiversityworkinggroup/biodiversityworkinggroup.htm 
accessed 2 November 2019.  
23 Rio +20 Future We Want Outcome Document 
https://sustainabledevelopment.un.org/index.php?menu=1298accessed 2 November 2019, para 16;  
24 A/Res/69/292 (6 July 2015): Development of an international legally binding institution under the United 
Nations Convention on the Law of the Sea on the conservation and sustainable use of marine biological 
diversity of areas beyond national jurisdiction. 
25 See webpage of Preparatory Committee https://www.un.org/depts/los/biodiversity/prepcom.htm accessed 2 
November 2019. 
26 A/Res/72/249.   
27 Ibid, art 2.   
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building.28  The first draft ILBI text was published in June 201929  after negotiations at two 
IGCs.30At the time of writing in late 2019, this draft has been discussed by states, IGOs and 
NGOs at IGC331 and a further draft is awaited.  There will be a fourth IGC in March-April 
2020 and a meeting at the General Assembly to adopt the ILBI later in that year.      
3 Mare Geneticum and Beyond  
This proposal uses as a base a proposal, Mare Geneticum, developed in the context of the 
ILBI by scientists (including one of the authors), lawyers and policy makers. It provides a fair 
means of encouraging and rewarding research and development into MGR from ABNJ, and 
of sharing the benefits resulting from this work.32  Points of particular interest here relate to 
the sharing with all of the results of research cruises, through the deposition of data in a series 
of linked public databases to enable further scientific activity, capacity building and later 
commercial product development; and to the initial researchers having an exclusivity period - 
and also the option of a paid extension to it (with amounts to be established with reference to 
the sector) with proceeds from this going to a biodiversity fund. Compliance with these 
information provision and payment provisions could be through a system of digital 
identifiers. In addition, Mare Geneticum proposed that the biodiversity fund would support 
capacity building for scientists from developing areas and that there would be prior electronic 
notification of research activity (alongside separate requirements for environmental impact 
assessments) in advance of the research cruise, with the details to be updated afterwards.33   
Elements of Mare Geneticum are included in the ILBI draft text.34  
Mare Geneticum was put forward in the context of provisions in UNCLOS regarding the 
rights to states to engage in marine scientific research,35 and that carrying out of that marine 
scientific research is to be subject to the freedom of the high seas36 which could mean that 
anyone could have access to the MGR on a first come first served basis and profit from it 
 
28 See analysis in E. Morgera, ‘Competence or Confidence? The Appropriate forum to Address Multi-Purpose 
High Seas Protected Areas’ 16 Review of European, Comparative and Internanational Environmental Law 
(2007) 1 and Warner n2, 162-4. 
29 Intergovernmental Conference on Marine Biodiversity of Areas Beyond National Jurisdiction, ‘Draft text of 
an agreement under the United Nations Convention on the Law of the Sea on the conservation and sustainable 
use of marine biological diversity of areas beyond national jurisdiction’, 17 May 2019 A/CONF.232/2019/6 
(June 2019 draft ILBI). 
30 President’s aid to discussions for IGC 1 A/CONF.232/2018/3 and Aid to Negotiations for IGC 2 A/CONF. 
232/2019/1*;  E. Mendenhall, E. De Santo, E. Nyman, R. Tiller, ‘A soft treaty, hard to reach: The second inter-
governmental conference for biodiversity beyond national jurisdiction’ 108 Marine Policy (2019) 103664 for a 
valuable review of the negotiation process at IGC 2 - 4.1.1 on MGR noting the “plodd[ing] by delegates” 
through a detailed “Aid to Negotiations” which contained various options; and D. Leary, ‘Agreeing to disagree 
on what we have or have not agreed on: The current state of play of the BBNJ negotiations on the status of 
marine genetic resources in areas beyond national jurisdiction’  99 Marine Policy (2019)  21-29 (Leary). 
31 See resources via ‘Third substantive session” https://www.un.org/bbnj/content/third-substantive-session and 
reports via Earth Negotiations Bulletin https://enb.iisd.org/oceans/bbnj/igc3/ both accessed 2 November 2019. 
32 T.Vanagt, A Broggiato, L.E. Lallier, M Jaspars, G. Burton and D Muyldermans, ‘Mare Geneticum: Towards 
an Implementing Agreement for Marine Genetic Resources in International Waters’ 27 in Freestone n7.   
33 See June 19 draft ILBI n29, arts 22-39. 
34 See June 19 draft ILBI n29, arts 10.1, 11.3 (a), 52.5.  
35 UNCLOS, art 238 see also art 240(d) referring to the rest of UNCLOS 
36 Although this is not an unfettered provision, see UNCLOS, art 87(1)(f) and art 87(2) referring notably to 
rights in respect of activities in ABNJ.  
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without the need to share any benefit arising.37  Yet UNCLOS also provides that the ABNJ, 
(and importantly its resources) are the common heritage of mankind.38 These two different 
approaches have given rise to significant debate on regarding the legal basis for benefit 
sharing in respect of MGR.39 Mare Geneticum provides a pragmatic solution. Further, Mare 
Geneticum is consistent with some other proposals for a holistic approach to benefit sharing 
in relation to MGR with a focus on technology transfer and capacity building and data 
sharing40 and for the generation of a common fund.41  There are also new arguments for 
benefit sharing to be a theorised, independent concept grounded in equity42 and one which 
delivers “deeper and cosmopolitan international cooperation”.43  
These proposals for benefit sharing, particularly from the theoretical perspective, could 
empower the taking of new positions to MGR in the ILBI. This new positions could draw on 
other benefit sharing regimes (beyond Nagoya)44 and also address issues which are arising 
from evolving attitudes and technology. 45  An example of such a point is the challenge to 
Mare Geneticum’s period of exclusivity on the basis that it entrenches the first mover 
advantage of the initial researcher, and in the view that there should rather be a sharing with 
all, from the start, of the information and samples gained from research cruises.46   This would 
 
37 Leary n30, 3.1; Glowka n8, 155 suggesting that MGR falls under freedom of the high seas155. 
38 UNCLOS, arts 133, 136, 137(2), 140.   
39 C. Salpin, ‘The Law of the Sea: A before and after Nagoya’  (Salpin) in Morgera et al n18, 153 -6; D Tladi, 
‘Conservation and sustainable use of marine biodiversity in areas beyond national jurisdiction: towards an 
implementing agreement’ in R Rayfuse (ed) Research Handbook on International Marine Environmental Law 
(Cheltenham, Edward Elgar, 2015) 259, 260-3; Heafey n16, 508-9;  K. Marciniak, ‘Margine Genetic Resources: 
do they Form Part of the Common Heritage of Mankind Principle?’ in L. Martin, C. Salondia, C. Hioureas (eds), 
Natural Resources and the Law of the Sea: Exploration, Allocation, Exploitation of Natural Resources in areas 
under National Jurisdiction and Beyond (JuristNet, 2017) engaging in particular with treaty interpretation under 
the Vienna Convention on the law of Treaties and levels of awareness of scientific opportunities, and concluding 
that MGR in the ABNJ is subject to freedom of the high seas but that there is a place for Part XI of UNCLOS 
regarding common heritage of have a place in regulation of these MGR. 
40 H. Harden-Davies and K. Gjerde, ‘Building Scientific and Technological Capacity: A Role for Benefit-
sharing in the Conservation and Sustainable Use of Marine Biodiversity beyond National Jurisdiction’ 33(1) 
Ocean Yearbook Online (2019) 377 (Harden-Davies and Gjerde), 394-5. 
41 Heafey n16, 518-21, building on the initiatives of the Global Commons Trust.  
42 E. Morgera, ‘The Need for an International Legal Concept of Fair and Equitable Benefit Sharing’ 27 The 
European Journal of International Law (2016), 353 (Morgera Need), 354, 357, 359, 368, 373, 380-3; E. 
Morgera, ‘Fair and equitable benefit-sharing in a new treaty on marine biodiversity: A principled approach 
towards partnership building? (BENELEX Working Paper No.16, 2018) (Morgera Fair and Equitable), pp.6-11, 
48, 54-7. 
43 Morgera Fair and Equitable n42, 51. 
44 Notably the International Treaty on Plant Genetic Resources for Food and Agriculture 2400 UNTS p303 
(Plant Treaty) and steps taken at the World Health Organization in relation to the sharing of viruses and 
pandemic supplies, and/or the First Global Plan of Action for Forest Resources 2014 http://www.fao.org/policy-
support/resources/resources-details/en/c/469497/ accessed 2 November 2019. See Morgera Fair and Equitable 
n42, 54; Claudio Chiarolla, ‘Intellectual property rights and benefit sharing from marine genetic resources in 
areas beyond national jurisdiction: current discussions and regulatory options’ 4(3) Queen Mary Journal of 
Intellectual Property (2014) 171-194 (Chiarolla), 190;  Correa n 8; Harden-Davies and Gjerde n40; A. Bonfanti 
and S. Trevisanut, ‘TRIPS on the High Seas: Intellectual Property Rights on Marine Genetic Resources’ 37 
Brooklyn Journal of International Law (2011) (Bonfanti and Trevisanut) 215-220 and 223-6. 
45 Muller n20 66, 70; Bonfanti and Trevisanut n44, 232. 
46 Siva Thambisetty, ‘Marine Genetic Resources beyond National Jurisdiction: Elements of a New 
Internationally Legally Binding Instrument” LSE Law Policy Briefing 32 2018 (Thambisetty), in particular 
value 6 “property begets property”.  
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undoubtedly increase the transfer of knowledge and opportunites for collaboration between 
scientists.    
An open approach to sharing with scientists can draw from the Plant Treaty,47 which created 
an opportunity (but not an obligation)48 for states to create farmers rights. There is also an 
African Model Law for the protection of farmers and regulation of access to biological 
resources.49   These instruments reflect a recognition of an equitable and sustainable base for 
special treatment to be accorded to farmers, in the light of the fact that they have stewarded 
the land over generations as primary custodians.50  Farmer’s Rights have been referred to as a 
possible analogy in the context of rewarding past conduct, in proposals for a new specific IP 
right to protect the needs of investors and bioprospectors.51 A different perspective to using 
Farmer’s Rights is pursued here. Scientists can fulfil a similar role to farmers - looking after 
nature and bringing about benefits for all - through their objective analysis of the MGR, and 
the sharing of this information (which will be considered further below).  Accordingly, 
scientists should be accorded rights in the ILBI, and these should move beyond the 
peripheral, optional rights in the Plant Treaty. There should be a mandatory benefit sharing52 
mechanism regarding the sharing of information, payments and provision of opportunities to 
participation in cruises. This should enable the virtuous cycle of activity to continue with 
contributions from scientists throughout the world.   
Such a cycle would accord less reward and arguably a reduced incentive to the initial 
researcher (including investors in them and any related companies).  Yet in addressing ABNJ 
there have been calls for more ambition and a focus on nature and the climate.53  From this 
starting point, and reflecting the points made above challenging a exclusivity based approach, 
 
47 See details in n44, and B. Fedder, Marine Genetic Resources, Access and Benefit Sharing: Legal and 
biological perspectives (Abingdon, Routledge, 2013) (Fedder), 115-6;      
48 Plant Treaty art 9; C. Chiarolla, S. Louafi and M. Schloen, ‘An Analysis of the Relationship between the 
Nagoya Protocol and Instruments relating to Genetic Resources for Food and Agriculture and Farmers’ Rights’ 
in Morgera et al, n18.  
49 Organization of African Unity model law https://www.wipo.int/edocs/lexdocs/laws/en/oau/oau001en.pdf 
accessed 3 November 2019,  art 4, 8, 12, 14 in particlar  art 15 restricting use bio resource and the risks of loss 
of the ecosystem. 
50 Plant Treaty,  arts 9, 13, 18; African model law art 21-6; C. Chiarolla, ‘Right to food and intellectual property 
protection for plant genetic resources’ in Christophe Geiger (ed) Research Handbook in Human Rights and 
Intellectual Property (Edward Elgar 2015) 539-50; Camena Guneratne, Genetic Resources, Equity and 
International Law (Edward Elgar 2012) 92-102; T. Adebola, ‘Access and benefit sharing, farmers rights and 
plant breeders rights: reflections on the African Model Law’ 9(1) Queen Mary Journal of Intellectual Property 
(2019) 105-121 (Adebola), 106; Morgera Need n42, 378-9. 
51 Federal Agency for Nature Conservation and IUCN, ‘A possible way forward’ (2011) 
https://www.bfn.de/fileadmin/MDB/documents/service/Skript_301.pdf accessed 3 November 2019 39-42. 
52 Compare June 2019 draft ILBI n29 reflecting uncertainty, art 11.3 (a)(b). See also study 4 on how domestic 
measures address benefit sharing prepared pursuant to Conference of Parties of the Convention on Biological 
Diversity Decision 14/20 exploring some existing national requirements  https://www.cbd.int/dsi-gr/2019-
2020/studies/#tab=1 accessed 30 November 2019.  
53 A.Vaughan, ‘David Attenborough on climate change “We cannot be radical enough”’ (New Scientist 9 July 
2019) https://www.newscientist.com/article/2209126-david-attenborough-on-climate-change-we-cannot-be-
radical-enough/ and David Attenborough documentary, ‘Climate Change – the Facts’ (May 2019) 
https://www.bbc.co.uk/programmes/m00049b1 https://www.bbc.co.uk/news/entertainment-arts-47988337 all 
accessed 29 October 2019 and from Pacific Islands Forum, ‘Forum Calls for Increased Level of Ambitions in 
New BBNJ Treaty’ https://www.forumsec.org/forum-calls-for-increased-level-of-ambitions-in-new-bbnj-treaty/  
accessed 2 November 2019. 
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this contribution will explore some pathways to bring about a more open and also more 
sustainable approach. 
4 The need to have regard to ecosystems and ecological perspectives    
 
Conservation and sustainable use, included in the title of the ILBI, have ecological 
dimensions.54  Ecosystems undergo constant evolution. Populations of species (which include 
MGR) are components of larger ecosystems, and ecosystems interact with other species and 
the non-living environment, contributing to the functioning of that larger ecosystem and its 
living components. 55 An ecosystem’s resilience – its ability to retain its structure and 
functions in the face of disturbance – can be impaired by human and natural stressors, which 
could render it a simpler ecosystem, less able to support a high diversity of species.56   
Warning signs currently abound that all ecosystems are under threat. Climate change is taking 
place against a backdrop of significant and accelerating global ecological degradation,57 with 
biodiversity loss equivalent to an extinction event,58 and other changes in planetary 
conditions such as ocean acidification at unprecedented levels.59   The message of a 2019 
report was that “nature and its vital contributions to people, which together embody 
biodiversity and ecosystem functions and services, are deteriorating worldwide”.60      
 
Accordingly, any use of MGR needs to interact with simultaneous efforts to reduce pressures 
on ecosystems. There should be a more visible, central place for regard to impact on ecosystems 
when working with MGR in addressing societal needs and/or commercial opportunities, and in 
the sharing of benefit in respect of this.61 The June 2019 draft negotiating text for the IGC3 
does display awareness of this issue. It includes a suggested provision in the general principles 
requiring all States to ‘[a]pply an approach that builds ecosystem resilience to the adverse 
 
54 J.M.Blair, S.L.Collins and A.K.Knapp, ‘Ecosystems as Functional Units in Nature’ 14 Natural Resources and 
Environment (2000) 150; F.S.Chapin III, P.A.Matson and P.Vitousek, Principles of Terrestrial Ecosystem 
Ecology (2nd ed, Springer, 2011), 3-22. 
55 S.A.Levin,‘Ecosystems and the Biosphere as Complex Adaptive Systems’ Ecosystems (198) 431; G.Harris, 
Seeking Sustainability in an Age of Complexity (Cambridge, Cambridge University Press, 2007), 19-26. 
56 C Folke, ‘Resilience: The Emergence of a Perspective for Social-Ecological Systems Analyses’16 Global 
Environmental Change (2006)  253, 257, 557, 570-1; CS Holling, ‘Understanding the Complexity of Economic, 
Ecological and Social Systems’ 4 Ecosystems (2001) 390; R.Biggs, G.D.Peterson and J.C.Rocha, ‘The Regime 
Shifts Database: A framework for analysing regime shifts in social-ecological systems 23 Ecology and Society 
(2018) 9. 
57 Millennium Ecosystem Assessment, Ecosystems and Human Well-being: Synthesis (Washington DC, Island 
Press, 2005); World Wildlife Fund, Living Planet Report 2018: Aiming Higher (World Wildlife Fund, 2018). 
58 J Rockström et al, ‘Planetary Boundaries: Exploring the Safe Operating Space for Humanity’ 14 Ecology and 
Society (2009) 32. 
59 International Geosphere-Biosphere Programme, Ocean Acidification Summary for Policymakers, (2013, Report 
from the Third Symposium on the Ocean in a High-CO2 World, Stockholm). 
60 IPBES, ‘Global Assessment Report on Biodiversity and Ecosystem Services’ IPBES/7/10/Add.1 p 3 Key 
message A. 
61 See further on this theme across the BBNJ and more widely, V. De Lucia, ‘The Ecosystem Approach and the 
BBNJ Negotiations (Working Paper 10 July 2019)  Available at SSRN: https://ssrn.com/abstract=3420988 or 
http://dx.doi.org/10.2139/ssrn.3420988  accessed 2 November 2019 and O Woolley, Ecological Governance. 
Reappraising Law’s Role in Protecting Ecosystem Functionality (Cambridge, Cambridge University Press, 
2014). 
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effects of climate change and ocean acidification and restores ecosystem integrity’.62  Such a 
provision could support regard to delivering resilience in delivering the ILBI.     
 
The first possible element of an ecological and ecosystem focussed approach would be for the 
ILBI to reflect current scientific practice, and its likely development, by engaging with MGR 
in a digital form. This would limit, to an extent, the need for physical samples.      
 5 The meaning of MGR 
 
The traditional starting point for relevant MGR activity was “in situ” – actually finding and 
working with the physical raw materials in the ABNJ. Samples would then be taken on to 
land where more work was done. There is a deep scientific cultural norm of samples being 
stored in respositories, say in oceanographic institutes or in museums such as the Natural 
History Museum in London. Working with MGR in these repositories can be termed “ex 
situ”.63 In theory, these materials are available for all to visit and use, consistent with the 
farming and stewarding analogy.  In reality, lack of human resource, record keeping and 
taxonomic challenges (such as uncertainty as whether this MGR is a species which has 
already began identified or whether it is a new one) has meant that not as many benefits are 
being taken from these MGR as would be desirable.64   
 
Developments in chemistry, bioinformatics and computer science have created new 
opportunities for working with MGR.65  Physical samples can be analysed and the genetic 
data (e.g. a short and unlikely unique example would be ATTCGTAAGC) established from 
individual organisms, metagenomes from an assemblage of microorganisms such as 
planktonic species, or chemical structures of derivatives such as proteins and metabolites.66  
This genetic information could then be shared67 in online databases such as the National 
Center for Biotechnology Information (NCBI, operated from the United States).68  This 
would enable wider dissemination without access to the physical MGR, and the genetic 
information could be the subject of further research and synthetically used and modified, 
possibly leading to new commercial products – if, as ever, there is sufficient time and money.  
 
In the past, the DNA was obtained on shore in a laboratory or on the research vessels after 
physical samples had been preserved. At the time of writing, however, DNA extraction and 
 
62June 2019 draft ILBI n29, art.5(b). 
63 See discussion in Kate/Laird n10, 3.6.2.  
64 See M Rabone et al, ‘Access to Marine Genetic Resoruces (MGR): Raising Awareness of Best-Practice 
through a New Agreement for Biodiversity Beyond National Jurisidiction (BBNJ)’ 12 Frontiers in Marine 
Science (2019) 520 https://doi.org/10.3389/fmars.2019.00520 (Rabone). 
65 Morgera Fair and Equitable n 42, 67-71. 
66 See eg M. E. Watanabe, ‘The Nagoya Protocol: The Conundrum of Defining Digital Sequence Information’  
69(6) BioSciences (2019) 480; TE Berry, BJ Saunders, ML Coghan, M Stat, S Jarman, AJ Richardson et al, 
‘Marine environmental DNA monitoring reveals seasonal patterns in biodiversity and identifies ecosystem 
responses to anomalous climatic events’ 15(2) PLoS Genet (2019) e 1007943.      
67 Rabone n64. 
68 See website https://www.ncbi.nlm.nih.gov/ accessed 2 November 2019. 
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sequencing devices have been developed which float or sit on the seafloor.  Examples are the 
MesoBot and devices using Oxford Nanopore sequencing systems.69  Such products can be 
used to deliver enough information for scientists to then replicate DNA sequences in the 
laboratory and use them as the base for further research and commercial development, 
without the need for the physical sample at all. This process would also involve additional 
significant work, as this in situ analysis would only give unassembled sequence data. The 
data needs to be assembled to a high degree of accuracy to begin the process of annotation to 
ascribe function to genes and this may require laboratory work and access to other annotated 
gene sequences.  
 
Looking forward, it is likely that there will be more in situ sequencing, through the advent of 
next generation sequencing technologies and practices. The use of these technologies in situ, 
and their implications, will need to be considered as part of the environmental impact 
assessment framework being developed elsewhere in the ILBI.70 Part of this will be the fact 
that these technologies could remove the need for raw materials to be collected, which would 
in turn reduce the scale of the environmental impact and ecosystem impact.71  Accordingly, 
the ILBI should cover data representing MGR samples from ABNJ, as well as the physical 
sample.72 If the ILBI does not, then the careful balances sought to be struck in it regarding 
benefit sharing will not apply to all activity based on MGR.73 Some support for the inclusion 
of data has been put forward at the IGCs74 and the issue is included as a possibility in the 
June 2019 draft ILBI, with definitions of MGR as “in silico”, “[digital] [genetic] sequence 
data and [and information]]”.75  Engaging with digital information in the ILBI would also 
align with the view that MGR should be seen as natural information (even when in its 
physical form). This is because genes contain information about heredity and future 
possibilities for functionality (even though as noted detailed work is needed to move from 
this to important research and commercial development), and there are calls for equal 
protection of the two forms of information.76    
 
 
69 See Woods Hole Oceanographic Institution, ‘Mesobot’ https://www.whoi.edu/what-we-
do/explore/underwater-vehicles/auvs/mesobot/ accessed 2 November 2019 and Oxford Nanopore Technologies 
https://nanoporetech.com accessed 22 November 2019  
70 See June 2019 draft ILBI n29, arts 22-41. 
71 K.D Prathapan, R. Pethiyagoda, K.S. Bawa, P.H. Raven, P.D. Rajan et al Divakaran et al, ‘When the cure 
kills – CBD limits biodiversity research; national laws earning biopiracy sqelch taxonomy studies’ 360 6395 
Science Mag Policy Forum (2018) 1405 (Prathapan)  
72 See also Charles Lawson and Michelle Rourke, ‘Open Access DNA, RNA and Amino Acid Sequences: The 
Consequences and Solutions for the International Regulation of Access and Benefit Sharing’ 24 Journal of Law 
and Medicine (2016) 96 (Lawson and Rourke) 11. 
73 See Thambisetty n46.   
74 See e.g., Earth News Bulletin 25.3.19 reporting on IGC 2: Caricom and Pacific Small Island Development 
States support the inclusion of resources, in situ, ex situ, in silio, digital sequence data and deriv, Turkey support 
inclusion of digital sequence data. 
75 June 2019 draft ILBI n29, arts 8 (2)(b) regarding application, 10(4) regarding access, 11(3)(a) and (b) 
regarding fair and equitable sharing of monetary and non monetary benefit, 13(3)(a) regarding monitoring, 42(c) 
(iii) regarding the objectives of capacity building and technology transfer and art 51(3)(c) regarding the clearing 
house. There is also the option that the ILBI would not cover this at all art 8(3)(b).  
76 Muller n20, 16 ,18, 20-1, 23.  
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Existing benefit sharing regimes, notably Nagoya, focus on physical genetic resource, so the 
proposal made here raises the important issue of having dual regimes. The question of digital 
sequence information is, however, currently being discussed in multiple forums including at 
the Convention on Biological Diversity,77 although uncertainty remains as to what definition 
and approaches will be chosen. For now, the discussion of new technology for genetic 
sequencing in situ raises another issue - the approaches taken to IP rights and to trade secrets. 
 
6 The approach to IP and trade secrets 
6.1 Context 
 
Increased technological development can bring with it more private sector involvement. This 
can bring with it greater desire for private control of the results of research.  This may seem 
unusual or heretical to scientists accustomed to norms (developed particularly in the context 
of human genome sequencing) of sharing data before and after publication.78 Limiting access 
is, however, quite consistent with values of property, immediate reward and control which are 
familiar to the commercial sector. This sector was also noted to have a role in developing 
natural products to address societal needs.  Further, involving the commercial sector in the 
pipeline to develop new products (often termed bioprospecting) has led to the increased wider 
understanding of global biodiversity as a whole.79 This has been invaluable as funding for 
surveying biodiversity in itself is often very hard to obtain.   
 
But even with this point it would be unwise to move to the other extreme and create an 
environment in which the commercial sector has too much power. This could have an overly 
negative impact on other scientific research, and on the benefits this other work could 
deliver80 and which could then be shared.81  Concern as the exercise and impact of private 
power has been seen in relation to human genes in the context of cloning (notably regarding 
 
77 CBD, ‘Digital sequence information on genetic resources’  https://www.cbd.int/dsi-gr/2017-2018/ and 
Commission for Plant Genetic Resources For Food and Agriculture, ‘Digital Sequence Information’ 
http://www.fao.org/cgrfa/topics/digital-sequence-information/en/ WHO, ‘Approach to Seasonal Influenza and 
Genetic Sequence Data under the PIP Framework 
https://www.who.int/influenza/pip/8bAnalysis_Draft1_17Sep2018_EN_hyperlinks.pdf?ua=1  all accessed 2 
November 2019 and ). See also study 1 science-based fact finding study on the content and scope of digital 
sequence information  prepared pursuant to Conference of Parties of the Convention on Biological Diversity 
Decision 14/20 https://www.cbd.int/dsi-gr/2019-2020/studies/#tab=1 accessed 30 November 2019. 
78 Bermuda Principles 1996 and Report from Wellcome Trust meeting, ‘Sharing data from large-scale 
Biological Projects: A System of Tripartite Responsibility” 2003  
https://www.genome.gov/Pages/Research/WellcomeReport0303.pdf accessed 2 November 2019. Lawson and 
Rourke n72. 108. See also reflections of this in OECD Guidelines for the Licensing of Genetic Inventions 2005 
http://www.oecd.org/sti/emerging-tech/36198812.pdf accessed 3 November 2019. 
79 See eg R.J. Quinn, P de Almedia Leone, G Guymer and J.N.A. Hooper, ‘Australian biodiversity via its plants 
and marine organisms. A high-throughput screening approach to drug discovery’ 74(4) Pure Appl. Chem. 2002, 
519–526; NatureBank at Griffith University https://www.griffith.edu.au/institute-drug-discovery/unique-
resources/naturebank accessed 2 November 2019. 
80 Prathapan n71, 63951406.  
81 C. Salpin and V. Germani, ‘Patenting of research results relating to genetic resources from areas beyond 
national jurisdiction: The crossroads of the law of the sea and intellectual property law’ 16(1) Review of 
European community and international environmental law (2007) 12-23 (Salpin and Germani), 16.  
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the BRCA gene and expressed sequence tags), 82  synthetic biology83 and, at a more 
downstream level, access to essential medicines.84  
 
6.2 Relevant rights 
IP rights (notable ones being patents, copyright and trade marks)  are held by private entities, 
pursuant to national legislation, in the context of an international treaty (TRIPS, 1994 under 
the WTO) which requires that WTO members have a system of IP rights.85 TRIPS also 
requires protection of confidential information86 and this is delivered in national laws as a 
mix of legislation and case law.87  IP and trade secrets confer private power (in respect of IP 
rights, for a limited period) over the results of innovation and creativity and over information 
if criteria are met for them to exist. In addition to the mandatory legal bases just mentioned, 
there are longstanding legal, economic and societal views in support of IP and trade secrets.  
Broadly, and reflecting some of the points made so far in this chapter, these are that IP rights 
and trade secrets encourage and reward innovation, and investment in it, to develop products 
for the benefit of all - and in the case of IP rights ensure disclosure of it, such that ultimately, 
there can be wider and unrestricted use of the innovation.88 So legally, and from an incentive 
perspective, the existence of IP rights and trade secrets, and their power, should not be 
ignored.   
States can and do, however, impose some limits on the power held by IP owners and on 
controllers of secret information. The key issue here is the extent to which the ILBI can and 
should impose obligations on states to do this to ensure that benefit sharing can come about.  
 
82 G. Matthijs and G-J B. Van Ommen, ‘Gene patents: from discovery to invention. A geneticist’s views’ 311 
(Matthijs and Van Ommen) and G. Van Overwalle, ‘Of thickets, blocks and gaps’  (Overvalle Thickets) 383, 
453 both in G. Van Overwalle (ed) Gene Patents and Collaborative Licensing Models: Patents Pools, 
Clearinghouses, Open Source Models and Liability Regimes (Cambridge, Cambridge University Press, 2009) 
(Overwalle); Nicola Lucchi, The Impact of Science and Technology on the Rights of the Individual (New York, 
Springer, 2016) (Lucchi) 99-103, 114-134, 141-162 
83 Alison MacLennan, Regulation of Synethic Bioloigy: BioBricks, BioPunks and BioEntrepreneurs 
(Cheltenham, Edward Elgar, 2018), 251 et seq.  
84 H. Hestermeyer, Human Rights and the WTO. The Case of Patents and Access to Medicines (New York, 
Oxford University Press, 2007) chapters 1 and 4; F. Abbott, ‘Managing the Hydra: The Herculean Task of 
Ensuring Access to Essential Medicines’ 393 and H. Klug, ‘Comment Access to Essential Medicines – 
Promoting Human Rights over Free Trade and Intellectual Property Claims’ 481  in K.E.  Maskus and J.H. 
Reichman (eds) International Public Goods and Transfer of Technology Under a Globalized Intellectual 
Property Regime (Cambridge, Cambridge University Press, 2005)  
85 Annex IC of Marrakesh Agreement Establishing the World Trade Organization (1994) 1867 UNTS 154 
(TRIPS), in particular art 9, 27  
86 TRIPS n85, art 39  
87 Eg in England and Wales/ EU Coco v AN Clark [1968] FSR 415, EU Directive 2016/943/EU on the 
protection of indisclosed know know and business information OJ L 157/1 16 June 2016. 
88 Lucchi n82, 10; Heafey n16, 502; F M Scherer, ‘The Innovation Lottery’ in R.C.Dreyfuss, D.L. Zimmerman 
and H First Expanding the Boundaries of Intellectual Property. Innovation Policy for the Knowledge Society 
(eds) (Oxford, Oxford University Press, 2001); K. E Maskus, ‘The Economics of Global Intellectual Property 
and Economic Development: A Survey’ in P. Yu (ed) Intellectual Property and Information Wealth (Westport, 
Praeger, 2006); C. Greenhalgh and M. Rogers, Innovation, Intellectual Property and Economic Growth 
(Princeton, Princeton University Press, 2010); Commission on Intellectual Property Rights, ‘Integrating 
Intellectual Property Rights and Development Policy’ (2002) http://www.iprcommission.org/ accessed 30 
October 2019. 
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IP has long been seen as potentially having some place in the ABNJ MGR process. In 2007 
the UN Secretary-General’s report on Oceans and the Law of the Sea engaged with the work 
of the World Intellectual Property Organization (WIPO) on genetic resources regarding 
access and benefit sharing, disclosure of the origin of genetic resources and the links between 
this and the patent examination process to establish novelty – which is a necessary 
requirement for a patent to be granted -  and also regarding the sharing of benefit. IP rights 
were included in the terms of the Working Group and information on IP was put before it.89 
The President’s Aid to Discussions for IGC1 asks whether the relationship between the ILBI 
and IP should be set out and if so how; 90  and  the President’s Aid to Negotiations for 1GC291 
and the June 2019 ILBI draft for IGC include several options on IP – although they are 
restricted to patents92 and have a focus on disclosure of origin.   
This contribution will not address this issue further, however it raises an important 
perspective. There has been some reluctance at the IGC to engage with patents and disclosure 
of origin, on the basis that patents were dealt with in other international fora.93  Yet from the 
practical side, it has been clear in WIPO documents (including a 2019 draft from the chair) 
that it is not proposed that the outcomes will engage with resources from beyond national 
jurisdiction94 and attempts to discuss the issue within TRIPS have stalled.95   There are also 
more IP issues which should be raised in the ILBI, and failing to engage with them could lead 
to outcomes which are explicitly or implicitly more supportive of private sector control of 
MGR.96   Further, engaging with IP in the ILBI would be consistent with an established body 
of scholarship and policy making which seeks to avoid fragmentation of legal regimes.97    
 
89 C Chiarolla, ‘Intellectual Property Rights Issues’ Paper 6, IUCN Information Papers for Intersessional 
Workshop on Marine Genetic Resources 2-3 May 2013  (Chiarolla IUCN), 37   
https://www.un.org/Depts/los/biodiversityworkinggroup/documents/IUCN%20Information%20Papers%20for%
20BBNJ%20Intersessional%20Workshop%20on%20MGR.pdf accessed 2 November 2019. 
90 PAD A/CONF.232/2018/3 25 June 2018 3.2.3.  
91 PAN 3 December 2018 A/CONF.232/2019/1* 3.2.3 and IUCN Commentary on June 2019 draft ILBI 
https://www.iucn.org/sites/dev/files/iucn_comments_on_bbnj_draft_text_-_august_2019.pdf accessed 2 
November 2019 (IUCN Commentary) p18, 19. 
92 June 2019 draft ILBI n29, art 12.2, 12.3, 12.4 and IUCN Commentary n91, p19 regarding risks of the ILBI 
being inconsistent with TRIPS regarding restrictions on approval of the grant of IP rights, in IGC 3 para 12.4 
(c).      
93 See eg Earth News Bulletin 25.3.19 from IGC 2  Caricom and PSIDS want sui generis approach to IP; G77/ 
China, African Group, Iran, Tonga, Federated States of Micronesia, Turkey, PNG, Sri Lanka and Cuba want IP 
included in the ILBI; Singapore want IP to be addressed in in existing mechanisms at WIPO and WTO; EU, 
Canada, US, Switzerland, Norway, Holy See, Japan, Korea, Russian Federation, Australia do not support IP 
rights being in the ILBI.   
94 WIPO/GRTKF/IC/28/4 (2014), art 4.1(e); WIPO/GRTKF/IC/30/4 2016, art 3.1(e); WIPO/GRTKF/IC/34/4 
2017, art 4(1)(e); draft report prepared by Chair of WIPO IGC on IPGRTKF 30 April 2019.  
95 See WTO review of art 27.3 (b) https://www.wto.org/english/tratop_e/trips_e/art27_3b_e.htm accessed 22 
November 2019 and proposals for new article 29bis TN/C/W/59 of 2011 See also valuable discussion in 
Claudio Chiarolla, ‘Intellectual Property from a Global Environmental Law Perspective. Key lessons from the 
implementation of patent disclosure requirements for genetic resources and traditional knowledge’ Benelex 
Working Paper No 22 (Chiarolla Benelex) exploring whether requiring action is introducing another substantive 
requirement which is not clearly mandated under TRIPS, or or whether it is more of a procedural point therefore 
raises questions for the Patent Co-operation Treaty. 
96 Salpin and Germani n81, 12-3. 
97L. R. Helfer, ‘Regime Shifting: The TRIPs Agreement and the New Dynamics of International Intellectual 
Property Law Making’  29 Yale Journal of International Law (2004) 1; Morgera Fair and Equitable n42, 58-9; 
G.Teubner and P. Korth, ‘Two Kinds of Pluralism: Collision of Transnational Regimes in the Double 
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Indeed, the draft ILBI already includes, as noted, a proposed engagement with climate change 
- which has its own regime.98 So the fact that an issue could be addressed in other regimes 
should not mean that it should not be considered in the ILBI.  From this starting point, the 
next section will explore other means by which IP rights could impose obstacles to benefit 
sharing; will identify opportunities to resolve this from within IP law; and will suggest how 
these points could be addressed within ILBI. These proposals will be consistent with, and 
also move beyond the suggested, less specific, wording in the draft ILBI that it is to be 
applied in a manner which respected the competences of and does not undermine relevant 
legal instruments,99 and that it should promote coherence with those instruments, providing 
they are supportive of and do not run counter to the objective of UNCLOS and the ILBI.100  
6.3 Patents   
Firstly, there is an issue about the extent to which patents could be and are being granted over 
subject matter which is too close to MGR in its original form - rather than, as is inherent in 
Mare Geneticum, MGR being the subject of innovation and transformed. Such patents would 
mean that there was private control over a fundamental natural resource from the very start. 
Others could then only use this with the consent of the patent owner, and this could reduce 
the innovation of these others in developing new commercial products and engaging in 
research.101 There is uncertainty about present practices in this respect. Analysis of patents 
identifies references to MGR102 with examples involving Green Fluorescent Protein,103 red 
algae104 and sea cucumbers.105 The mere existence of such patents does not mean, however, 
that the right to control covers the MGR itself. There is a need for detailed analysis of the 
substance of patents, moving beyond data mining and empirical review of the landscape, to 
 
Fragmentation of World Society’ in M. A. Young (ed) Regime Interaction in International Law: facing 
fragmentation (Cambridge, Cambride University Press, 2012) 24, 41 with relevant challenges identified in 
conflicts between traditional approaches to confidentiality of indigenous groups and bringing about free use of 
information; regarding benefit sharing and farmers rights outside the ABNJ, see Chiarolla Benelex n95, section 
6  and Adebola n50, 112. 
98 United Nations Framework Convention on Climate Change 1992 1771 UNTS p107 which arose from the 
Earth Summit as did the Convention on Biological Diversity. 
99 June 2019 draft ILBI n29, art 4(3) first part. 
100 June 2019 draft ILBI n29, art 4(3) second part. 
101 Chiarolla IUCN n89, 40; Chiarolla 44, 178-9; Heafy n16, 520-1. 
102 Chiarolla n44, 177; P. Oldham, ‘WIPO Patent Landscape report Marine Genetic Resources’ (2019) 
https://www.wipo.int/edocs/pubdocs/en/wipo_pub_947_6.pdf accessed 2 November 2019 looking beyond 
patents to publications, and funding sources, species, though a data mining approach,  explored 391191 
scientific publications and 461380 patents, data from Global Biodiversity Information Facility; R Blasiak, J-B. 
Jouffray, C.C.C. Wabnitz, E. Sunstrom and H. Osterblom et al ‘Corporate Control and global governance of 
marine genetic resources’ Sci Adv 2018 exploring the ownership of patents. 
103 Jellyfish green fluorescent protein expression in plants WO199602765A1 (1996); B Verberue, ‘Patent 
pooling for gene-based diagnostic testing’ in Overwalle n82, 18.  
104 Breeding method of high-temperature-resistant stichopus japonicus strain  (2016 - CN106259067A; 
CN106259067B – China, which has led to product development by LBD Marine Technology, ‘About Agar’ 
http://en.libangda.com/products-and-service/about-agar/about-agar#bit_olwy3 accessed 2 November 2019. 
105 Preparation method of marine bacteria-derived kappa-carrageenase gene and recombinase (2016- 
CN105950640A; CN105950640B - China) which has led to product development, see X. Ru, L. Zhang, 
‘Development strategies for the sea cucumber industry in China’ 37(1) Journal of Oceanology and Liminology 
2019 300-312.  
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establish the extent to which this is so. Patents over raw MGR should not in theory exist, as 
patents must be new, inventive, the invention is to be capable of industrial application and not 
be excluded.106  The June 2019 ILBI draft included the valuable proposal that there shall be 
no patenting except when the MGR modified by human intervention results in a product 
capable of industrial application.107   
This contribution develops this point in a new direction: in addition to clarifying when 
patents could be obtained, the ILBI could imposed limit on the power which is to be 
conferred by states. TRIPS provides that states can impose such restrictions on the rights of 
the patent owner, as long as they are limited, do not unreasonably conflict with a normal 
exploitation of the patent and do not unreasonably prejudice the legitimate interests of the 
patent owner, taking into account the legitimate interest of others (“the three step test”).108 
Given this, and the research issue identified above, the ILBI could provide that states should 
provide in their national laws that research must be able to be continued in relation to an 
MGR innovation which is the subject of a patent. It is also suggested that the ILBI should 
provide that states are to impose this limit even if research is done for commercial purposes 
or by a commercial entity.  This is because there is diversity across national laws regarding 
the scope of research exceptions regarding commercial activity.109  The approach would also 
remove uncertainties about what activities should properly be viewed as commercial. Non 
commercial activity could end up as commercial, in the immediate or longer term;110 and 
those who may traditionally be perceived as non commercial actors (say those from 
universities) may be encouraged by their universities or may simply choose to set up their 
own companies to develop products, while also seeking to pursue collaboration and 
community.111     
TRIPS also provides that states can require sharing of patented innovation through a 
compulsory licence, to respond to national emergencies.112 Given the discussion so far 
regarding the place of MGR related innovation in responding to climate change, the ILBI 
should provide that states must include in their national laws compulsory licensing of patents 
in respect of energy transitions or ecologically sustainable products. TRIPS requires, 
however, that this licensing is in return for the payment of adequate remuneration.113  Given 
the complex arguments regarding the positive (as well as problematic arguments) regarding 
the power of IP rights and the need for investment,  it is likely that in the present context this 
 
106 TRIPS, art 27(1); Chiarolla IUCN n89, 37-8. 
107 June 2019 draft ILBI n29, art 12.3 first sentence. 
108 TRIPS, art 30. 
109 Monsanto v Stauffer [1985] RPC 515 and Auchinloss v Agricultural & Veterinary Supplies [1997] RPC 649 
compare German approach Clinical Trials II [1997] NJW 3092; see analysis in F. Humphries, ‘Shellfish patents 
kill experimentation: defences for sharing patented aquatic general materials in aquaculture’ 37(4) European 
Intellectual Property Review (2015) 210-224, 213-4. 
110 Correa n8, 13-14. 
111 Correa n8, 15-6.  
112 TRIPS art 31, in particular (b). This can also be argued to be necessary when there is no alternative eg Brigit 
Verberue, ‘Patent pooling for gene-based diagnostic testing’ in Overwalle n82, 17, 18 exploring Green 
Fluorescent Protein (see also n103) and also innovation in respect of rice and Huntingdon’s disease. 
113TRIPS, art 31(h). 
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could mean zero.  Adequate does not, however, mean the same as a full commercial market 
rate.   
The next section will explore the place of other IP and trade secrets in benefit sharing in 
respect of MGR. This issue is not recognised, or at least not indirectly, in IGC debate and in 
official documents generated so far. It is suggested that this should be addressed and this 
point has made in contributions by the authors to the commentary of the International Union 
on the Conservation of Nature on the June 2019 draft ILBI.114  
6.4 Database, copyright and trade secret: repositories 
6.4.1 Problem 
This wider IP inclusion argument will be developed here in the context of databases and 
repositories, which were explored above, particularly in the context of digital sequences.  At 
present, DNA sequence data can be deposited at one of 3 global databases – NCBI115 (in the 
United States, discussed above) under the term Genbank, European Bioinformatics Institute 
(EMBL - EBI, Europe)116 and DDBJ (Japan).117 Together, these form the International 
Nucleotide Sequence Database Collaboration (INSDC) and they share all DNA sequence data 
on a daily basis. Each has different tools to interpret and process the data, meaning that data 
downstream from the DNA sequence will differ in each one of these in terms of format, 
content and processing.  A pragmatic outcome regarding the future of repositories would be 
for the existing arrangements for collecting and sharing DNA to continue and develop, with 
the ILBI requiring an overall metadatabase. Within this, copyright118 (and also related rights, 
such as the database rights which exists in the EU)119 and trade secrets120 can, as will be seen, 
be relevant to the manner of operation of these and other databases and to the level of benefit 
sharing which can occur.   
Copyright, database rights and trade secrets do not require a registration process to exist. For 
copyright to exist, there must be a work. An individual piece of data would not be enough121 
but there could be copyright in a report of a cruise or planned cruise with details of location 
and findings, as this would count as a literary work.122 Further, depending on national laws, 
copyright could exist in respect of a collection of smaller pieces of information which is 
original in the sense of not copied and reflecting skill, labour and judgment in their 
 
114 IUCN Commentary n91, p 19. 
115 See n68.  
116See website https://www.ebi.ac.uk/ accessed 2 November 2019. 
117 See website https://www.ddbj.nig.ac.jp/index-e.html accessed 2 November 2019. 
118 For a wider introduction to copyright, see A Brown, S Kheria, J Cornwell, M Iljadica, Contemporary 
Intellectual Property:  Law and Policy (5 ed) (Oxford, Oxford University Press, 2019) (Brown), 31-203, 219-
231. 
119 For a wider introduction to database rights, see Brown n118, 238-251; EC Directive 96/9/EC on the legal 
protection of databases O.J. L 77 11 March 1996 20-28 (Database Directive). 
120 For a wider introduction to trade secrets, see Brown n118, 697-725.  
121 Exxon Corporation v Exxon Insurance [1982] Ch 119 - no copyright in the word “Exxon”. 
122 TRIPS, art 9 encompassing Berne Convention arts 1 and 2. 
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collection;123 in the EU member states a different test now applies, with the need for it to 
result from some intellectual creativity.124 For database rights to exist for a set of information, 
including a collection of DNA, there must be substantial investment in obtaining, verifying or 
presenting existing information.125 There will be a relevant trade secret if information is not 
in the public domain, has value because it is secret and reasonable steps have been taken to 
make sure it is secret.126   
Depending on the methods by which information is provided and stored on the repositories, 
the attitudes taken by the information supplier and the relevant national law, these three legal 
bases rights could apply to material which the ILBI may state is to be in public databases or 
repositories.127   Finally, copyright will also exist128 (and indeed in some cases software 
patents may be granted) 129 over the software which actually operates the databases and 
repositories. In terms of impact, copyright confers the possibility of private control of the 
reproduction of the work containing the information;130 database rights control the extraction 
or re-utilisation of whole or substantial part of contents of database;131 trade secrets control 
use of the information itself;132 and copyright and patent over the database could control the 
ongoing method of operation. These rights could lead, then, to refusals to supply the 
information in the first place, to requests that there will be no onward disclosure without the 
making of a payment, or that the database can only continue with the payment of a (or larger) 
fee.133    
There are suggestions that this is already a reality, with arguments regarding the Convention 
on Biological Diversity that key information is not being shared fully as it is the subject of 
confidentiality claims and that it is therefore difficult to assess whether fair and equitable 
benefit sharing is being delivered.134 Further, reflection on some existing databases and 
repositories in respect of DNA confirms that IP related issues could arise.135 Careful analysis 
of existing genetic resources databases has explored arrangements which database operators 
 
123 The traditional position in the UK, see Ladbroke v William Hill [1964] 1 WLR 273, Interlego AG v Tyco 
Industries [1989] AC 217 compare US decision Feist Publications v Rural Telephone Service Co 499 US 340 
finding no copyright in alphabetical listng of names 
124 Infopaq International A/S v Danske Dagblades Forening C-5/08 [2009] ECDR 16   
125 Database Directive, art 7; British Horseracing Board v William Hill Organization Ltd Case C-203/02 [2005] 
RPC 13. 
126 TRIPS, art 39(2); Coco v Clark n87; Trade Secrets Directive, art 2(1).   
127 Chiarolla IUCN n89, 42; Chiarolla n44, 184; Lawson and Rourke n72,116.  
128 TRIPS, art 10.  
129 Lawson and Rourke n72,116. For a wider introduction to this complex issue and the different approaches 
taken across countries, see Brown n118, 435- 465 see in particular Re Bilski 545 F 3d 943 and Alice 
Corporation v CLS Bank International 572 US 208; Symbian v Comptroller General of Patents Designs and 
Trademarks [2008] EWCA Civ 1066; G03/93 Programs for Computers [2010] EPOR 36. 
130 See eg UK Copyright Designs and Patents Act 1998, s16(1)-(3) 
131 See eg UK Copyright and Rights in Database Regulations 1997 No. 3032 (implementing the Database 
Directive) 12(1). 
132 Coco v Clark n87; Trade Secrets Directive, arts 3, 4. 
133 Fedder n47, 119-120.  
134 Muller n20, 33, 39-41 67. 
135 Chiarolla n44, 183; Lawson and Rourke n72, 103. 
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have chosen to take to IP and trade secrets136 and has identified strong themes of sharing 
across publicly funded databases. Yet in this landscape there is also a place for IP. The terms 
and conditions of NCBI’s GenBank provide that material which is uploaded to GenBank may 
be the subject of IP rights although no restrictions are imposed on further use of information 
which is uploaded.137 The combined INSDC has a policy of free and unrestricted access to 
the records in their databases.138  Looking more widely, the BioBricks Initiative involves 
standard interchangeable DNA parts that have defined functions and that can be used in the 
construction of synthetic biology systems. Its goal is for “all genes and vectors that are 
synthesized and distributed through the 10k genes project [to] be solidly in the public domain 
and free of third-party rights”.139 Further, Biobricks makes genes available free of charge and 
checks that they are not the subject of patent sequence specific patent claims.140 Yet 
Biobricks’ terms and conditions provide that if IP rights exist then they are to be respected 
and that if submissons to it are the subject of IP rights, then details of this are to be 
provided.141    
The above discussion reveals some wide embracing of sharing but also alongside it instances 
of models with an embedded respect for IP rights. Further, the sharing approach – which is so 
positive for science - cannot be relied upon to continue. Funding arrangements may come to 
an end,142 government policy may change regarding support of service, or a private provider 
may provide software to the database and then choose to take a new approach.  
6.4.2 Solution 
In the light of this, the ILBI should focus on the sharing and disclosure requirement of the 
suggested metarepository.143  There has been some engagement with the issue, albeit without 
a focus on the underpinning legal issues just discussed.   Calls have been made for databases 
to be open144  and there are references in the June 2019 draft145 for “a clearing house 
 
136 Charles Lawson, Heath Burton and Fran Humphries, ‘The important place of information in the evolving 
legal and policy framework for the conservation and sustainable use of the world’s plant genetic resources for 
food and agriculture’ EIPR 2018 40(4), 243-259, 247, 249-50, 251,  253, 255-6 and table 1; Lawson and Rourke 
n72, 100-2, 104, 111-2; see also study 3 on public and private databses of digital sequence information on 
genetic resources prepared pursuant to Conference of Parties of the Convention on Biological Diversity 
Decision 14/20 exploring some existing national requirements https://www.cbd.int/dsi-gr/2019-
2020/studies/#tab=1 accessed 30 November 2019 (Database Study).  
137 See webpage ‘GenBank submission types’ https://www.ncbi.nlm.nih.gov/genbank/submit_types/ accessed 3 
November 2019. 
138 INSD ‘Collaboration Policy’ http://www.insdc.org/policy.html accessed 3 November 2019 rules 1-3.  
139 K. Kendall, S. Pownall, L. Kahl, ‘Bionet 10k Genes Project Documentation v1.0’  
 https://www.reddit.com/r/bionet/comments/7bo7gz/bionet_10k_genes_project_documentation_v10/ accessed 3 
November 2019. 
140 BioBricks Foundation, ‘The Free Genes Project’ https://biobricks.org/freegenes/ accessed 3 November 2019 
141 Ibid, ‘Explanation’ 1 bullet 3, ‘Submission’ 1 bullet 2.  
142 See eg the journay of the Arabidopsis Information Resource - funded by National Science Foundation, then 
core staff group set up Phoenix Bioinformatics (not for profit) then to subscription offering with different levels 
of access, all made available after one year https://www.arabidopsis.org/. For an example of a subscription 
database, see Marinlit http://pubs.rsc.org/marinlit/ both links accessed 3 November 2019.  
143 See discussion on this issue in Chiarolla IUCN n89, 41-2, 43; Chiarolla n44, 181-3.  
144 Fedder n47,122-176; Rabone n64.  
145 June 2019 draft ILBI n29, art 51, 51.2, 51.7. 
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mechanism with a web based platform to provide open access to MGR”.146   The draft ILBI 
also suggests, however, that due regard is to be had to the confidentiality of information 
being provided to the platform.147   
Building on the discussion above, this suggests that information provided could be 
incomplete.  Further, there are a variety of positions regarding the meaning of “open 
access”.148  To a lawyer the word may suggest immediately available, for no fee – just as seen 
(up to a point) in relation to BioBricks. This approach to open access is used in the context of 
licensing models149 which IP owners have chosen to embrace such as CAMBIA Bios,150 
Creative Commons151  and the Eco-Patent Commons (which is now closed).152  These all 
provide specific licensing terms or conditions of use (for example approaches taken to be 
taken to commercial use or acknowledgement) and have no licence fee. These frameworks 
operate on a voluntary level, however, so in this sense they do not deliver a base for a 
mandatory ILBI approach.  It should also be borne in mind that “open access” can have 
different meaning for scientists.  The focus there is not on IP and payment, but on ensuring 
that the database provides the necessary information for scientists and interoperability with 
other databases, publications and networks.153 Finally, the term “open access” can have a 
cultural meaning, in terms of delivering fairness, equity and community sharing. This can be 
seen in the FLOSS (Free Libre and Open Source) Movement, which is deeply opposed to 
property rights and control.154  
Debate, and ultimately clarification, is therefore needed on this point in the ILBI. If one 
wished to require fee-free access, IP and trade secrets issues could arise.155 This is because 
requiring that the control conferred by IP rights and trade secrets could not be relied upon, 
could move beyond the relevant flexibilities within TRIPS.156  TRIPS has no national 
emergency provision in TRIPS regarding copyright and trade secrets. The proposal made 
above regarding patents could be adapted to cover patents over relevant software used by 
international metarepositories.  A version of the three-step test applies, however, to 
 
146 See previous discussion in Leary n30, 21-29 and June 2019 draft ILBI n29, art11.3 (b). 
147 June 2019 draft ILBI n29, art 51.7 and IUCN Commentary n91, p 60.   
148 See IUCN Commentary n91, pp 17, 59.  
149 E. van Zimmeren, ‘Clearinghouse mechanisms in genetic diagnosis’ in Overwalle n82, 71-9.  
150 See website http://www.copyleftlicense.com/licenses/cambia-plant-molecular-enabling-technology-bios-
license-version-15/view.php accessed 3 November 2019; N. Berthels, ‘Case 8. CAMBIA’s Biological Open 
Source Initiative (BiOS)’ in Overwalle n82. 
151 See website https://creativecommons.org accessed 3 November 2019.  
152  See CEF Spotlight, ‘Welcome to the Eco-Patent Commons’ http://www.corporateecoforum.com/welcome-
to-the-eco-patent-commons/ accessed 29 October 2019. Note debate about the value of the patent made 
available – B. H. Hall and C. Helmers, ‘Innovation and diffusion of clean/green technology: Can patent 
commons help?’ 6(1) Journal of Environmental Economics and Management (2013) 33-51.  
153 Rabone n64. 
154 See GNU Operating System website https://www.gnu.org/philosophy/floss-and-foss.en.html accessed 3 
November 2019. A. S. Taubman, ‘Several kinds of ‘should’’ (Taubman) 223 in Overwalle n82.    
155 These issues were raised in IUCN Commentary in the context of clearing houses and check points, n91, p20. 
156  Building on points made in Chiarolla n44, 175-8.  
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copyright.157 It could be argued again that fee-free access158 was too much of an interference 
with the power of the right and could be a disincentive for the development of valuable and 
needed software. A solution could be to require mandatory sharing with a reasonable 
payment would be made to the owner of the copyright or database right.159 This could also 
build on arguments that IP rights can be seen not as a right to exclude but as a right to 
payment,160 or as a right to distribute and bring about uses of technology.161 To ensure that 
the payment can be made while also maximising the needs of benefit sharing and science, the 
ILBI could provide that these payments received could be passed on by the IP owner to the 
biodiversity fund to enhance further activity.  For those unable to pay, the fund could make 
the payments to the IP owner.  This would also be consistent with arguments for a more 
stewardship approach to be taken to IP.. It has been argued that the (there) “patent owner-as-
steward is not asked to ‘conserve’ the subject matter of his property in the same way as the 
landowner is required to conserve the natural world under this model, but there is no reason 
why they should not be expected to take environmental concerns into account in exploiting 
the invention”.162 The relevant environmental concerns here would be enabling the sharing of 
information about MGR and the enabling of further research which could, inter alia, 
contribute to ecologically sustainable development.    
 
Trade secrets remain. TRIPS does not engage with defences to trade secrets. National laws do 
have established defences, notably in the UK that use is in the public interest,163 and this is 
reflected to an extent in the EU Trade Secrets Directive.164 The inherent nature of trade 
secrets makes it a challenge, however, to construct a forward looking regime – defences can 
operate only in the context of a leak of information. The public interest defences could be a 
base for the ILBI requiring proactively that details are shared of information obtained on 
research cruises, as this would in turn enable further scientific research by others. This would 
also be consistent with obligations under UNCLOS for states to take steps to actively 
promote the transfer of information and knowledge resulting from marine scientific 
research.165  The issue remains, however, of the level of interference with the incentive to be 
involved in marine biodiversity research, particularly given the more measured suggestions 
seen to be needed regarding IP rights.  The binary nature of trade secrets makes it difficult to 
 
157
See n106, 108, 112-3 122; TRIPS, art 9, encompassing Berne Convention, art 9(2).   
158 For other possibiltiies, see E. van Zimmeren, ‘Clearinghouse mechanisms in genetic diagnosis’ in Overwalle  
n82, 63, 68; Chiarolla n44, 190-1.  
159 See also S Dusollier, ‘The commons as a reverse intellectual property’ in H. Howe and J. Griffiths (eds) 
Concepts of Property in Intellectual Property Law (Cambridge, Cambridge University Press, 2013) (Howe and 
Griffiths) 265-6  267, 268 seeing the role of exceptions to copyright as creating a functional public domain.  
160 D. L Burk, ‘Critical analysis: property rules, liability rules and molecular futures. Bargaining in the shadow 
of the cathedral” in Overwalle n82.  
161 Taubman n154, in Overwalle n82, 225, 226-7, 233, 239; D. Lametti, ‘The concept of the anticommons. 
Useful, or ubiquitous and unnecessary?’ in Howe and Griffiths n159, 251-2.   
162 H. R. Howe, ‘Property, sustainability and patent law’ in Howe and Griffiths n159, 299 (quote), 298-300; 
Blasiak n15.   
163 Attorney General v Observer Ltd [1990] 1 AC 109 involving diaries of a member of security services.    
164 Trade Secrets Directive, art 5. 
165 UNCLOS, art 244.  
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introduce a solution based on exceptions to the right.  It is suggested, then, that a period of 
secrecy can continue for a period (say 6-12 months), similar to the existing Mare Geneticum 
proposal in respect of exclusivity, and then the information must be made available to all.  If 
there is disclosure of information within this initial period, there should be a defence if 
information is used to contribute to bringing about ecologically sustainable practices.   
6.2.3 Delivery 
The draft ILBI of June 2019 shows some willingness to engage with IP as it has an IP clause 
- albeit with a focus on  patents.166 The more minimalist approach also remains (as also seen 
in the Aid prepared for IGC2), 167 with the draft having suggested clauses providing that 
implementation of the ILBI is to be in a manner consistent with the WIPO and the WTO, or 
ensuring that IP rights are supportive of and do not run counter to the IBLI’ s objectives.168 
There is also the prospect of the parties choosing not to have an IP provision in the ILBI. 
Such an approach would bring about the fear expressed by some IGC delegates that if IP and 
MGR is not addressed in the ILBI, it may not be addressed anywhere.169 The position 
discussed at WIPO suggests that this may be so in respect of disclosure of origin. IP appears, 
however, to be moving more into the mainstream. At IGC3 in August 2019, there was a 
confidential informal informal meeting on the place of IP170 and there were a growing 
number of IP experts,171  as well as a side event co-ordinated by the authors exploring the 
possible place of IP.172   
The next section moves along the development and benefit sharing pipeline and evaluates 
how the use of MGR could be traced through IP and elsewhere.  
7 Tracing 
Patents and disclosure of origin are one form of doing this tracing. The focus here is more on 
the wider picture. The June 2019 draft ILBI refers to the possible assigning of an identifier to 
MGR collected in situ,  ex situ and digital sequence information.173 Concerns have been 
raised that tracing would be burdensome and costly and a deterrent to scientific activity.174  
This is not necessarily so.175  There is existing technology though Global Positioning System 
 
166 June 2019 draft ILBI n29, art 12. 
167 PAN 3 December 2018 A/CONF.232/2019/1* 3.2.3 Options II and III 
168 June 2019 draft ILBI n29, art 12.1, 12.2 first section. See IUCN Commentary n91, p 18-19, calling for 
specific engagement with flexibilities under TRIPS.  
169 Earth Negotiations Bulletin 25 (2019) 25 March 2019 ‘in corridors’, noting intense talk on IP and benefit 
sharing and frustrations about IP shifting from place to place in a “merry-go-round” of intellectual property fora.  
170 A/CONF.232/2019/8/Rev.1 
171 Personal view of the authors from their own experience. 
172 See Schedule of side events 
https://www.un.org/bbnj/sites/www.un.org.bbnj/files/bbnj_igc_iii_side_events_schedule_final_eng.pdf accessed 
3 November 2019, 22 August event 2, orgnaised by authors with IUCN and Deep Ocean Stewardship Initiative.  
173June 2019 draft ILBI n29, art l1.3(3)(a) and see IUCN Commentary n91, p20. 
174 See eg Earth Negotiations Bulletin 25 (2019) 25 March 2019  - Caricom wanted a non intrusive track and 
trace system.  
175 Morgera Fair and Equitable n42, 68-76; R. Wynberg and S. A. Laird, ‘Fast Science and Sluggish Policy: The 
Herculean Task of Regulating Biodiscovery’ 26(1) Cell Press Review Trends in Biodiscovery (2018)  1-3;  M.A. 
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data and use of digital object identifiers, that would render tracing the journey of MGR along 
the scientific and commercial supply chain as both possible and best practice. Repositories 
can – and importantly already do - have an important role including in the allocation of 
identifiers.  Further examples, in addition to those mentioned above, are ChemSpider176 and 
metadatabases such as Ocean Biographic Information System (OBIS).177 Each takes care of a 
different subset of the information and interlinks at different levels: they track MGR,  
taxonomy and publications (and also patents which are related to MGR) as part of established 
practice in sample management and scientific practice including through the requirements of 
funders and of journals.178     Looking forward, evolving technology, such as blockchain and 
distributed ledgers may enable information to be traced more readily.179  
So a full technological solution would be possible to track and trace all MGR through the 
biodiscovery pipeline in its different forms.  Yet this full solution is not yet available to all. 
There would be a need for existing practice to be made available globally, in a capacity 
building technology transfer effort, so that common standards for data can be shared fully.  
Work is ongoing on this already through OBIS through the Darwin Core Archive.180  
Nonethess, it is suggested that the ILBI should  require a sample unique identifier and set out 
the functionality requirements which are to be delivered from time to time, with the method of 
this to be monitored through a new central body envisaged in the ILBI.181  The ILBI should 
not require the use of any particular product. The suggested functionality would not in fact 
make it possible to know where any MGR sample is at any given time or who is using a 
genetic sequence. The sample unique identifier would mean, however, that the sample can be 
to traced back to its origin, enabling payment into the biodiversity fund to be made as 
relevant from product sales or patent royalties.   
The tracing and payment frameworks could fund the sharing of information and opportunities 
set out in this contribution, in addition to the payments which IP owners may choose to make 
to the biodiversity fund.  This is important given that, as an example, one existing repository 
discussed above, Genbank, has an annual global cost of [??].182 The fund could also, as 
noted, make payments to IP owners if the research user is not able to do so.  From this base, 
the next section will consider the range of the benefit sharing obligations. 
8 MGR and benefit sharing: toward future proofing183 
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8.1 Timing of benefit sharing  
As noted at the start of this contribution, Mare Geneticum raised the prospect of a period of 
exclusivity for the initial researcher, and this was seen to have been the subject of some 
criticism. It has been argued at the IGC that the ILBI should not condone or require a 
privatising approach to the samples.184 Further, a more open approach to sharing would be 
aligned with an emerging cultural approach in science and in data curation, that information 
should be FAIR (findable, accessible, interoperable and reusable).185  Indeed, the proposals 
made above regarding metadatabases and sharing of information seek to deliver this later in 
the process.   
It is suggested here that this mandatory sharing should apply from the start, with the 
requirement of exclusivity for the initial researcher set aside.  It is suggested that making 
MGR samples (physical and digital) openly accessible from the start will be possible in many 
cases and if so, this should be done. With the physical sample, the collection may be limited 
depending on the amount which the scientists recovered from the reseach cruise – and 
bearing in mind also that from an ecological and ecosystem focussed approach, the samples 
removed should be as limited as possible. In such cases, it is proposed that the researchers 
that instigated the collection should be given the first chance to work on the limited physical 
samples. Given the points made in Mare Geneticum, it is hoped that this would include 
researchers from developing nations. When there is ample material collected, in a manner 
which means that it could be used in other projects, it is proposed that this should be shared 
between researchers for multiple non-competing research uses. This would reflect a practice 
used by the Norwegian Marine Biobank, MarBank.186 This approach would be efficient and 
equitable for the environment and for science. It would make the best use of existing 
materials, reduce the need to repeat collection and generate overlapping collections, and 
enable data to be acquired in parallel on the same sample, thus increasing knowledge of 
biodiversity. 
 
184 Earth Negotiations Bulletin 25 (2018)12 September 2018 at IGC 1 arguments by PSIDS. 
185 European Marine Biological Research Infrastructure Cluster (EMBRIC), ‘ABS principles for preserving, 
accessing, exploring and sharing marine genetic resources’ (April 2019), http://www.embric.eu/node/1759 
accessed 3 November 2019; S. Stall et al, ‘Make all scientific data FAIR’ 570 Nature (6 June 2019) 27-29;  H. 
Pierce et al, ‘Credit data generators for data refuse’ 570 Nature (6 June 2019) 30-32. 
186 See website https://www.imr.no/marbank/en accessed 3 November 2019. 
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Figure 1. A simplified schematic showing the steps in the marine biodiscovery process. 
Sampling in situ is the first step, and this can be to collect a whole organism (such as a 
spongs or seacucumber) or a sediment which contains millions of microorganisms. A whole 
organism can be extracted to obtain bioactive compounds, or alternatively, pure microbial 
cultures are isolated from a marine sediment. These pure cultures can be grown at a larger 
scale to obtain bioactive compounds. In parallel, many studies now obtain genetic sequence 
data on organisms which allows the identification of what the organism might be able to 
produce. Eliciting the production of such compounds can be difficult as the factors needed to 
do this are not well understood. Extracts and pure compounds are subjected to biological 
screening (e.g. against cancer, infections or inflammation) or functional screening (e.g. as 
enzymes for washing powders, or cosmeceuticals). Taking products to market can be a long 
and difficult process, as for pharmaceuticals, or it can be quicker for products for which 
regulation is less stringent. 
8.2 Scope of benefit sharing  
A second issue is when in the pipeline the obligations to share benefit building on work with 
the MGR should end.  Should the obligation only cover basic collection and genetic analysis? 
Should it encompass all research and development building on the MGR to any extent in its 
different forms?  Should it extend to commercial activity187 which started with the MGR, 
modified the MGR, and/or which used products and research which had been based on work 
with the MGR?  They may be a long way down a development pipeline away from the MGR 
- yet this phase of commercialisation could be said not to have been possible without the 
MGR.       
The challenges of identifying what is commercial has already been seen above in respect of 
research. There is also the question of how far one should seek to gain benefit from, or indeed 
users should seek to recognise and repay, what they have gained from MGR - even if they 
 
187 June 2019 draft ILBI n29, art 1.15 varying approaches.  
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have also added to it through significant financial investment, time and expertise.  A later 
drawing of the line would mean that more activities would be subject to the benefit sharing 
regime. This could be objected to on the basis that by this time there would already have been 
a fair and equitable return to all from the earlier use made of the MGR and benefit sharing in 
respect of it.  
When there is an IP right it has been suggested, building on existing theories of “bounded 
openness”, that there should be sharing of financial benefit in respect of the natural 
information discussed above. 188 This draws not on the nature of the activity (such as 
commercial or non commercial, in or ex situ, physical or information) but on the fact that the 
MGR information does and should flow freely. That proposal then is that payments could 
made, therefore, of a fixed royalty from the IP right into a fund, with the amount to depend, 
with echoes of Mare Geneticum, on utilisation levels and the industry involved.189  Alongside 
this, again with echoes of Mare Geneticum, that work proposes that details are to be shared of 
where the MGR was found, so that the increased information will create more choice 
between MGR which could be used - which would lead in turn to more demand and also 
more cooperation, more complementarity and less overlap and so less damage to fragile 
ecosytems from activity.190   
The draft ILBI of June 2019191 explored what activities would be covered by utilization of 
resources. Yet the location in the pipeline of the activities, and how the work on MGR has 
been the subject of say second or third generation activity, has not been explored in the 
negotiations.  IP rights will not always exist so it is proposed that they should not be the base 
for a solution.  Proposals made in the context of animal and plant breeding at the Convention 
on International Trade in Endangered Species of Wild Fauna and Flora limited regulation 
from this perspective to the first, second, third and fourth generation. 192  This genetic 
perspective does not, however, map directly on to product development. The pharmaceutical 
products which are ultimately approved by regulators may have gone through 10 or so 
developments beyond the original MGR.     It is suggested, therefore that benefit sharing will 
only apply to the first three generations of a product, by each innovator, which are brought to 
market drawing on MGR. Issues could of course arise about innovators moving from one 
company to another and of businesses restructuring. For now, however, we consider that this 
provides a useful starting point. 
9 Delivering an IP based ecosystem approach to benefit sharing 
The final step of this contribution is to draw together, and enhance, the delivery of an 
ecosystem and ecological approach to benefit sharing. As noted, there could be compulsory 
licensing of patented inventions to deal with national emergencies which could include 
ecologically sustainable products in exchange for an adequate payment which could to be 
 
188 Muller n20, 24, 117.   
189 Muller n20, 8, 66, 88.  
190 Muller n20, 73-4, 77, 79 figure 5.1, 80. 
191 IUCN Commentary n91, p7, art 1.15 Alt 2.   
192 CITES Resolution Conf. 10.17 (Rev.CoP14) on Animal Hybrids, art 1(a) and (d).    
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paid into the diversity fund; an option for reasonable payments made for use of copyright and 
database works in relation to repositories to be paid into the diversity fund; and for use of 
secret information to pursue ecological goals to be covered by a public interest defence or for 
a payment after a period to the biodiversity.  This provision of some ongoing reward for the 
innovator and IP owner engages with one of the incentive strands set out at the start of this 
chapter. The sharing of the information and payments in some cases to the biodiversity fund 
to support activity by developing country scientists engages with the second strand.   
Further incentives could be included in the ILBI to encourage choices for MGR to be used to 
develop ecologically sustainable technologies rather than, say, other health treatments and 
cosmetics. “Ecologically sustainable technologies” could be defined by the central body 
likely to be established under the ILBI or through a new role given to an existing body. This 
could draw from work under the United Nations Framework Convention on Climate Change 
in respect of “environmentally sound technologies”,193 the European Patent Office regarding 
categorisation and “sustainable technologies”194 and work by several patent agencies 
(including the UK and Brazil) for fast track examination of “environmentally friendly” and 
“green” innovation.195   
One pathway to do this may appear surprising, given the points made above.  The ILBI could 
impose fewer requirements to share the innovation or public interest defences in respect of 
these technologies and rely on the fact that, based on a traditional approach incentive and 
innovation approach to IP, the more power conferred, the more incentive there would be to 
choose to innovate in this area.   Yet even if this approach did encourage more research, the 
issue would remain of the limits on the innovation and activity which the rights would 
impose on the activity of others during the term of the patent or while the information was 
secret.  There could be the hope that the instances explored across this contribution of patent 
owners choosing to share their innovation could lead to increased use by others of 
ecologically sustainable technology. Yet a key theme across this contribution has been that 
this approach to sharing cannot and should not be relied upon.   
A preferable approach, then, which is indeed also rather market based, would be for a 
decreased payment to be made to the biodiversity fund by those developing and selling 
ecologically sustainable solutions. This could encourage innovation in this space. It could 
also be justified on the basis that such innovators are through this innovation choice already 
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Agreement Annex to Decision FCCC/CP/2015/L/9/Rev.1 art 10(1); Technology Mechanism 
https://unfccc.int/ttclear/support/technology-mechanism.html and Global Environment Facility under the Poznan 
Strategic Programme on Technology Transfer Webpage  https://www.thegef.org/topics/technology-transfer and 
Case Studies https://www.thegef.org/sites/default/files/publications/GEF-TechTransfer-lowres_final_2.pdf,  
https://unfccc.int/resource/docs/publications/tech_for_adaptation_06.pdf  all accessed 4 November 2019 
194 Class Y02 and Yo4S - EPO webpage, ‘Sustainable technologies’ https://www.epo.org/news-
issues/issues/classification/classification.html.  
195 UKIPO Green Channel https://www.gov.uk/guidance/patents-accelerated-processing; A. Dechezlepretre and 
E. Lane, ‘Fast-tracing green patent applications’ WIO Magazine (2013) 
https://www.wipo.int/wipo_magazine/en/2013/03/article_0002.html accessed 4 November 2019.   
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paying debts to the ecosystem which were incurred by removing the MGR or going down to 
the seabed to analyse it and establish its digital sequence information.   
10 Conclusion  
The ILBI negotiations move closer to a solution. The closing remarks of the facilitator of the 
MGR discussions at IGC3 noted key issues to include how the definition of MGR engages 
with digital information, whether benefit sharing should be mandatory and its modalities and 
triggers and whether to address IP rights and if so how.196 This contribution has sought to 
contribute to these issues for marine diversity in the ABNJ.  
The prospect of commercial development with MGR, private activity in respect of new 
technologies and increased argument for regard to the protection of ecoystems require a new 
approach to MGR and benefit sharing.  If this is not done, then activity will fall outside the 
ILBI. This will render the ILBI at best incomplete and at worst undeliverable, with the option 
to engage more directly with ecological approaches being lost.   This contribution has 
developed a new ecosystem and ecologically-focussed approach building on the intersections 
between law and science, property and openness, commercial products and scientific 
research, physical and digital, the past and the future and normative and workable.  It has 
provided a new contribution which can be of use in the ILBI negotiations, in future legal and 
scientific debates which involve public and private perspectives and in the development of 
benefit sharing and its intersection with sustainability, science and other areas of law.  
Proposals have been made regarding definitions of MGR, engagement with IP and trade 
secrets, tracing the place of exclusivity, the timing, funding of activities covered by benefit 
sharing and a market-based system to encourage innovation in ecologically sustainable areas. 
They have avoided fragmentation and engaged in by intersystemic dialogue. The proposals 
made here are consistent with existing laws and would ensure that the benefit sharing goals 
can delivered, rather than being cast aside through an unquestioning acceptance of the power 
of private rights. The proposals do not change IP law, rather engage with opportunities which 
exist within IP law for states to introduce some permitted exceptions and require sharing.  
It is a challenge to future proof entirely the ILBI. But the proposals made here are an 
important step towards this, for science and for law. 
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